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Abstract
Background: The selective absorption of nutrients and other food constituents in the small
intestine is mediated by a group of transport proteins and metabolic enzymes, often collectively
called 'intestinal barrier proteins'. An important receptor that mediates the effects of dietary lipids
on gene expression is the peroxisome proliferator-activated receptor alpha (PPARα), which is
abundantly expressed in enterocytes. In this study we examined the effects of acute nutritional
activation of PPARα on expression of genes encoding intestinal barrier proteins. To this end we
used triacylglycerols composed of identical fatty acids in combination with gene expression profiling
in wild-type and PPARα-null mice. Treatment with the synthetic PPARα agonist WY14643 served
as reference.
Results: We identified 74 barrier genes that were PPARα-dependently regulated 6 hours after
activation with WY14643. For eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and oleic
acid (OA) these numbers were 46, 41, and 19, respectively. The overlap between EPA-, DHA-, and
WY14643-regulated genes was considerable, whereas OA treatment showed limited overlap.
Functional implications inferred form our data suggested that nutrient-activated PPARα regulated
transporters and phase I/II metabolic enzymes were involved in a) fatty acid oxidation, b)
cholesterol, glucose, and amino acid transport and metabolism, c) intestinal motility, and d)
oxidative stress defense.
Conclusion: We identified intestinal barrier genes that were PPARα-dependently regulated after
acute activation by fatty acids. This knowledge provides a better understanding of the impact
dietary fat has on the barrier function of the gut, identifies PPARα as an important factor controlling
this key function, and underscores the importance of PPARα for nutrient-mediated gene regulation
in intestine.
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The small intestine is the primary site for digestion and
selective absorption of nutrients and other food constitu-
ents. Absorption of these molecules across the intestinal
epithelium is mediated mainly by multiple transmem-
brane transporters that principally belong to two super-
families, namely the solute carrier (SLC) and the ATP
Binding Cassette (ABC) superfamily of transporters. SLC
transporters located at the apical membrane of entero-
cytes are responsible for the selective uptake of macronu-
trients, such as di- and tripeptides, hexoses and fatty acids
[1]. In contrast, ABC transporters are efflux transporters
responsible for the active removal of substances, includ-
ing nutrients such as cholesterol, regulating their intracel-
lular concentrations [2]. Besides their presence in plasma
membranes, SLC and ABC transporters are also located in
intracellular organelles, such as mitochondria or peroxi-
somes, thus regulating intracellular and transcellular sol-
ute transport.
In addition, it has become clear that the small intestine is
an important metabolic active organ, to a great extend
responsible for the first-pass metabolism of nutrients and
xenobiotics [3,4]. Numerous metabolic reactions occur in
enterocytes, including those typically referred to as phase
I and phase II metabolism. Phase I metabolism includes
oxidative, peroxidative, and reductive metabolism of
endogenous compounds and drugs, mediated by cyto-
chrome P450 isoenzymes (CypP450s) [5]. Phase II
metabolism often succeeds phase I metabolism and yields
mainly more hydrophilic metabolites, mostly by conjuga-
tion, thereby increasing the water solubility of lipophilic
compounds. The most important phase II enzymes are
sulfotransferases (Sults) [6,7], UDP-glucuronosyltrans-
ferases (Ugts) [8], glutathione S-transferases (Gsts) [9,10],
N-acetyltransferases (Nats) [11], and epoxide hydrolases
(Ephs) [12]. Several ABC transporters are responsible for
the excretion of metabolites resulting from phase I and
phase II enzymatic transformations [2].
There is increasing interest in the molecular mechanisms
underlying the beneficial or adverse effects of foods and
food components. Nutrients impact gene expression
mainly by activating or suppressing specific transcription
factors [13,14]. The most important group of transcrip-
tion factors involved in mediating the effect of nutrients
and their metabolites on gene transcription is the super-
family of nuclear receptors, which consists of 48 members
in the human genome [15]. This superfamily is subdi-
vided into six families [16], of which the NR1 family is
most relevant to nutrition. One important group of recep-
tors that mediates the effects of dietary fatty acids and its
derivatives on gene expression are the Peroxisome Prolif-
erator Activated Receptors (PPARs, NR1C) [16-18]. Three
PPAR isotypes, α (NR1C1), δ (also called β) (NR1C2),
and γ (NR1C3) are distinguished and characterized by dif-
ferent biological roles. Transcriptional regulation by
PPARs requires heterodimerization with the retinoid X
receptor (RXR; NR2B) [16,19,20]. When activated by an
agonist, the PPAR/RXR heterodimer stimulates transcrip-
tion via binding to DNA response elements (PPREs)
present in and around the promoter of target genes.
Besides upregulating gene expression, PPARs are also able
to repress transcription by directly interacting with other
transcription factors and interfere with their signaling
pathways, a mechanism commonly referred to as transre-
pression [21].
PPARα has been shown to be expressed at a high level in
the small intestine [22]. Moreover, the average Western
diet contains a high amount of triacylglycerols [23] that
are hydrolyzed to monoacylglycerol and free fatty acids
before entering the enterocyte [24]. As a result the small
intestine is frequently exposed to high levels of natural
PPARα agonists. However, currently little is known about
the effects of PPARα activation by dietary fats on gene
expression in small intestine. Although in several studies
small intestinal gene expression was studied after high-fat
feeding [25-27], the specific role of PPARα remains to be
elucidated.
Here, we take advantage of a unique experimental design
using triglycerides composed of identical fatty acids in
combination with gene expression profiling to examine
the effects of individual dietary fatty acids on intestinal
gene expression in mice. By conducting these experiments
in wild-type and PPARα -/- mice, and by limiting the
exposure time to 6 hours, we were able to elucidate the
specific, direct contribution of PPARα in regulating the
expression of transport and phase I/II metabolism genes
in small intestine.
Results and discussion
Effect of acute PPARα activation with OA, EPA, DHA and 
WY14643
In this study we investigated the role of PPARα on the
expression of genes encoding for transport proteins and
phase I/II metabolic enzymes, collectively called barrier
proteins, which are responsible for the selective absorp-
tion and metabolism of food components. Since we are
specifically interested in the role PPARα plays in nutrient-
mediated gene regulation, we used and compared in our
studies 3 natural agonists normally found in the diet
[oleic acid (OA, C18:1), eicosapentaenoic acid (EPA,
C20:5) and docosahexaenoic acid (DHA, C22:6)]. As ref-
erence we used the synthetic agonist WY14643. We ana-
lyzed gene expression 6 hours after oral gavage, thus we
primarily studied the direct effects of PPARα activation.
This time point was chosen because in a pilot experiment
we found that after an oral fat load plasma triacylglycerolPage 2 of 13
(page number not for citation purposes)
BMC Genomics 2008, 9:231 http://www.biomedcentral.com/1471-2164/9/231levels peaked at 2–3 hours post loading and almost
returned to basal levels after 6 hours (data not shown),
indicating that at that point most of the fat bolus has
passed through the enterocytes, and sufficient time
remained for transcriptional events to occur. Expression
of transport and phase I/II metabolism genes (barrier
genes) was studied using microarrays. The Affymetrix
GeneChip Mouse Genome 430 2.0 array comprised of
45,038 probesets, representing 16,579 unique genes.
Annotation information from Affymetrix was queried to
compile a list of transport and phase I/II metabolism
genes present on the array (for details, see methods sec-
tion). This set consisted of 944 probesets, encoding for
529 unique genes, and was used throughout all analyses.
We identified 9,426 significantly expressed genes in small
intestine, of which 264 were barrier genes.
As expected, of all agonists used in this study, acute treat-
ment with WY14643 provoked the most pronounced
response, both with respect to the number of regulated
genes and the magnitude of the fold changes. Treatment
with WY14643 resulted in the PPARα-specific differential
expression of 74 transport and phase I/II metabolism
genes (Table 1), of which 32 were expressed at higher lev-
els and 42 genes were reduced in wild-type mice com-
pared to PPARα-null mice (for the full list of regulated
genes please see additional data, Table 1). On the other
hand, treatment of wild-type and PPARα-null mice with
OA identified only 19 PPARα-dependently regulated bar-
rier genes (Table 1). Of these, 13 were induced and 6
repressed (additional data, Table 2). Treatment with EPA
and DHA resulted in 46 and 41 PPARα-dependently regu-
lated barrier genes, respectively (Table 1). Activation of
PPARα by EPA increased the expression of 32 genes and
suppressed 14 genes (additional data, Table 3), whereas
for DHA these numbers were 22 and 19, respectively
(additional data, Table 4).
In Bünger et al [22] we reported that under basal (control)
conditions only 21 genes were differentially expressed in
small intestine of wild-type mice compared to PPARα-
null mice. The currently investigated barrier gene set
includes 2 of these genes, Slc25a20 and Cyp4a10, which
were both expressed at lower levels in the null mice. We
found that expression of Slc25a20 was only slightly ele-
vated after acute treatment with WY14643, EPA, and
DHA, which indicates that the regulation of Slc25a20 by
PPARα may be of less relevance during (nutritional) acti-
vation of PPARα. In contrast, the fold induction of
Cyp4a10 observed after acute treatment with WY14643,
EPA and DHA was much larger than the basal difference,
which implies that for this gene activation of PPARα is of
importance.
When comparing the list of barrier genes that were
PPARα-dependently regulated after acute treatment with
WY14643 with that of a long-term (5 day) exposure exper-
iment [22], we found an overlap of 74% (additional data,
Table 5). This indicates that short-term regulation evoked
with synthetic agonists is maintained for at least 5 days.
Hirai et al [28] very recently reported their study in which
they identified seven nutrient and drug transporters that
were PPARα-dependently regulated in small intestine
after 3 days exposure to two synthetic agonists. In con-
cordance with their data, we found that all except 2 of
these transporters were regulated after acute treatment
with WY14643 as well. In addition, we observed that
these carriers were also PPARα-dependently regulated by
DHA and EPA. Like Hirai et al, we did not observe a
PPARα-dependent regulation of Pept1 (Slc15a1), the first
intestinal nutrient transporter shown to be PPARα-
dependently regulated during fasting [28,29].
To characterize the importance of PPARα in controlling
expression of small intestinal transporters and phase I/II
metabolic enzymes, we compared the fraction of PPARα-
dependently regulated genes of the barrier gene set with
that observed for all genes (Table 1). For treatment with
OA the percentages were 7.2% and 5.4%, respectively, for
the set of barrier genes and all expressed genes. This differ-
ence was not statistically significant (p = 0.11). However,
the other two natural agonists showed a significantly
higher percentage of regulated genes for the barrier gene
set than for all genes; for EPA this percentage was 9.3% for
all genes, whereas 17.4% of the barrier genes were regu-
Table 1: Number of PPARα-dependently regulated genes after treatment with different agonists
OA EPA DHA WY14643




508 19 874 46 894 41 1218 74
Percentage 5.4 7.2 9.3 17.4 9.5 15.5 12.9 28.0
Number of PPARα-dependently regulated genes and corresponding percentages for all genes and the barrier gene set after activation with OA, 
EPA, DHA, and WY14643. The percentages relate to the total number of expressed genes (9,426) and all barrier genes (264), respectively.Page 3 of 13
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and 15.5% respectively (p < 0.001). For WY14643 we
observed an even larger difference between all genes and
the barrier gene set; 12.9% respectively 28.0% of the genes
were regulated in a PPARα-dependent manner (p <
0.001). These results imply that PPARα plays an impor-
tant role in regulating small intestinal gene expression of
transporter and phase I/II metabolic enzymes.
Overlap between OA, EPA, DHA and WY14643 treatment
We also determined the overlap of PPARα-dependently
regulated genes between the different treatments. Most of
the genes regulated upon treatment with OA were not reg-
ulated by DHA and EPA (Figure 1A) or WY14643 (data
not shown). Only four genes, i.e. Slc27a4 (Fatp4),
Cyp4F16, Cyp2c65, and Abcd3 were regulated upon all 4
treatments. For these genes additional qRT-PCR analyses
were performed, which confirmed the array results (Table
2). There was considerable overlap between the genes
affected by EPA, DHA or WY14643 treatment (Figure 1B).
These overlapping genes behaved the same in all treat-
ments, i.e. they were either increased or suppressed in
wild-type compared to PPARα-null mice upon all treat-
ments. In Table 6 of the additional data the complete list
of overlapping genes is presented. It is likely that OA treat-
ment affected fewer genes, because the mice may be
adapted to this fatty acid since they were fed a diet based
on olive oil three weeks before gavage (for details, see
methods section). In addition, it is generally accepted that
polyunsaturated fatty acids activate PPARα better than
monounsaturated fatty acids [30-33], which is in line with
our result that OA activated less genes PPARα-depend-
ently than EPA and DHA. Although the overlap between
WY14643-, EPA-, and DHA-regulated genes was high, we
still observed differential gene activation between these
treatments. The exact mechanism(s) underlying these dif-
ferences are currently unclear, but we speculate this may
be partially due to the differential recruitment of coactiva-
tors such as Src-1, Med1, Pgc1α, and p300 by the three
agonists [34-37]. Alternatively, hitherto unknown addi-
tional signaling routes not shared by the three agonists
may exist.
Functional implications of acute PPARα activation in small 
intestine
A summary of functional outcomes of PPARα activation
by the agonists inferred from our data is presented in table
3. Although in this study we only determined mRNA lev-
els, it has been reported that for the majority of genes the
mRNA levels reflect protein abundance very well [38,39].
We therefore allow ourselves to speculate about the func-
tional consequences of nutritional PPARα activation.
Nevertheless, these implications should ultimately be
evaluated in follow-up studies.
Role of PPARα in intestinal fatty acid oxidation
It is well established that PPARα serves as a master regula-
tor of fatty acid catabolism, which is also apparent from
our data [22,40]. Various transporters and phase I
enzymes involved in fatty acid uptake and oxidation were
PPARα-dependently regulated (Table 3). Although the
extent varied somewhat, all 4 agonists regulated long
chain fatty acid uptake, mitochondrial and peroxisomal β-
oxidation, ω-oxidation, and the metabolism of energy-
yielding substrates (glycogenolysis and Krebs cycle). For
most genes this regulation was agonist-independent and
is consistent with earlier findings [41-43]. It is known that
enhanced fatty acid β-oxidation is correlated with reduced
severity of inflammatory bowel disease [44]. Furthermore
it has been shown that WY14643 treatment caused a
reduction of colon injury in a murine DNBS experimental
colitis model [45] and that WY14643 treatment might
have an anti-inflammatory effect in the small intestine
[22]. It has been reported that the expression of Octn2
(Slc22a5), involved in apical carnitine uptake, is induced
by WY14643 and clofibrate [46-48]. Here we showed that
also EPA and DHA induced expression of Octn2. Recently
it has been reported that two functionally relevant poly-
morphisms in the Octn2 (Slc22a5) gene are associated
with increased risk for inflammatory bowel disease
[49,50], and that Octn2 expression is decreased in rats
with induced inflammatory bowel disease [51]. Taken
together, our data imply that nutritional activation of
PPARα might be therapeutically valuable for patients with
inflammatory bowel disease.
Table 2: Confirmation of microarray results
WY14643 EPA DHA OA
Gene symbol FC (MA) FC (qPCR) FC (MA) FC (qPCR) FC (MA) FC (qPCR) FC (MA) FC (qPCR)
Fatp4 (Slc27a4) 1.7 (0.24) 2.2 (0.28)* 1.5 (0.14) 1.7 (0.30)* 1.4 (0.14) 1.5 (0.09)* 1.4 (0.16) 1.6 (0.41)*
Abcd3 2.8 (0.38) 4.9 (0.75)* 1.7 (0.11) 2.0 (0.28)* 1.8 (0.08) 2.7 (0.50)* 1.4 (0.10) 2.0 (0.22)*
Cyp2c65 2.6 (0.34) 3.7 (0.69)* 2.3 (0.24) 2.8 (0.51)* 2.5 (0.48) 3.9 (1.13)* 1.7 (0.23) 2.7 (0.94)*
Cyp4F16 1.9 (0.36) 2.0 (0.44)* 1.5 (0.14) 1.3 (0.30)* 1.4 (0.17) 1.5 (0.25)* 1.9 (0.34) 2.5 (0.36)*
Microarray results were confirmed with qPCR. FC = Fold change, MA = microarray, qPCR = quantitative PCR. For the qPCR analysis: mRNA levels 
were standardized to cyclophilin; expression in the PPARα-null mice was arbitrarily set to 1. Significance was determined by a Bayesian t-test (array 
data) or unpaired student's t-test (qPCR data), * = p-value <0.05. Data are means ± standard error (n = 4–5).Page 4 of 13
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Expression of the apical cholesterol uptake transporter
Npc1l1 was PPARα-dependently suppressed after treat-
ment with WY14643, EPA, and DHA (Table 3), as also has
been observed after fenofibrate treatment [52] and PPARδ
activation [53]. It is known that treatment with WY14643
for 5 days induced expression of Abca1 [54]. Here we
show that Abca1 is also acutely regulated after PPARα acti-
vation. Abca1, which promotes cholesterol efflux at the
basolateral membrane to Apo-AI for HDL formation [55-
58] was increased after treatment with WY14643 and EPA.
Functionally these results suggest that less cholesterol is
absorbed from the lumen and more cholesterol is trans-
ferred to Apo-A1, resulting in reduced intracellular choles-
terol levels in enterocytes. Enterocytes likely compensate
for this by increasing the activity of HMG-CoA reductase,
as has been reported before [59-61].
PPARα regulates intestinal nutrient transport and 
metabolism
Expression of the apical glucose uptake transporter Sglt1
(Slc5a1) and the basolateral glucose efflux transporter
Glut2 (Slc2a2) was PPARα-dependently repressed after
WY14643 treatment. Furthermore, WY14643, EPA, and
DHA all reduced expression of the apical mannose and
glucose uptake transporter Sglt4 (Slc5a9), suggesting that
PPARα activation results in reduced glucose transport
through the intestinal wall. In addition, several transport-
ers involved in the amino acid metabolism were PPARα-
dependently regulated (Table 3). Gene expression of
small intestinal apical uptake as well as basolateral efflux
amino acid transporters was PPARα-dependently sup-
pressed. Furthermore, activation of PPARα reduced
expression of Slc25a12 (Aralar1), which is involved in the
malate-aspartate shuttle [62]. These effects are in line with
data that showed PPARα-mediated downregulation of
genes involved in hepatic amino acid metabolism
[40,63]. For liver it is suggested that amino acids are con-
served for local synthetic processes, including protein and
purine synthesis during for instance proliferation [64]. In
the small intestine villus length is increased after
WY14643 treatment [22], which implies that also in the
small intestine amino acids are conserved for local ana-
bolic processes. Taken together, our results suggest that
PPARα activation leads to a diminished (neutral) amino
acid flux through the enterocyte.
PPARα regulates intestinal motility
Expression of the serotonin transporter Slc6a4 (Sert) was
decreased after treatment with WY14643, EPA, and DHA
(Table 3). Serotonin is a neurotransmitter secreted by
enterochromaffin cells and is considered to play a key role
in functioning of the gut, initiating peristaltic reflex path-
ways and facilitating propulsive activity [65].
Inactivation of serotonin is crucial to limit its activity, and
this is mediated by Sert [66]. The observed reduced expres-
sion will result in a diminished activity of Sert, which in
turn may increase intestinal motility [66]. Serotonin is
detoxified by sulfation inside the enterocyte [67]. The api-
cal sulfate import seems to be reduced as gene expression
of the uptake transporter Slc13a1 (Nas1) was decreased.
This might be a response to the decreased uptake of sero-
tonin. We also showed that the dopamine transporter
Dat1 was PPARα-dependently upregulated after EPA and
OA treatment (Table 4). Dopamine increases contractile
force of intestinal motility [68], thus more dopamine
likely results in increased intestinal motility. Altogether,
we believe it is likely that PPARα is involved in regulating
intestinal motility. Our data suggest that in feeding condi-
tions PPARα activation may result in speeding-up intesti-
nal motility.
PPARα diminishes effects of oxidative stress
Oxidative stress results from an imbalance between for-
mation and degradation of pro-oxidants or decreased cel-
lular antioxidant protection mechanisms and may result
in increased cell damage and apoptosis [69]. Many genes
included in our barrier gene set, such as CypP450s, Gsts,
and several Slc transporters, are involved in oxidative
stress and were PPARα-dependently regulated. CypP450s
induce oxidative stress by oxidative, peroxidative, and
reductive metabolism of endogenous compounds and
drugs [5], whereas Gsts are involved in the defense against
oxidative stress by catalyzing the conjugation of glutath-
ione to a wide variety of endogenous and exogenous elec-
trophilic compounds [70]. Various CypP450 genes were
PPARα-dependently upregulated (Table 4), which is in
line with data obtained from liver [40]. However, since
not all CypP450 genes are expressed in both organs, the
regulated genes were not identical. Many Gsts were upreg-
ulated by activation with WY14643, EPA, and DHA (Table
3). In addition, various Slc transporters involved in oxida-
Overlap of PPARα-dependently regulated genes between the four agonistsFigure 1
Overlap of PPARα-dependently regulated genes 
between the four agonists. The numbers in the Venn 
plots represent the numbers of PPARα-dependently regu-
lated genes for each treatment. A) Overlap between OA, 
EPA and DHA, B) Overlap between EPA, DHA, and 
WY14643.Page 5 of 13
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Table 3: Overview of regulated processes
Gene symbol Probeset ID FC WY FC EPA FC DHA FC OA Function
Fatty acid oxidation
Fatp4 (Slc27a4) 1424441_at 1.7 1.5 1.4 1.4 Apical long chain FA uptake [76]
Cact (Slc25a20) 1423109_s_at 6.8 2.6 2.4 nc Carnitine cycle in mitochondrial β-oxidation [62]
Octn2 (Slc22a5) 1421848_at 7.7 3.2 4.2 nc Apical carnitine uptake for mitochondrial β-oxidation [48]
Fatp2 (Slc27a2) 1416316_at 2.2 1.6 nc nc Has acyl CoA properties to activate FA for subsequent 
peroxisomal β-oxidation [86]
Abcd3 1416679_at 2.8 1.7 1.8 1.4 Transport of VLFA over the peroxisomal membrane for 
peroxisomal β-oxidation [77]
Cyp4a10 1424853_s_at 1447.2 120.2 160.3 nc ω-oxidation [87]
Cyp4b1 1416194_at 1.7 nc nc nc ω-oxidation [87, 88]
Cyp4f16 1417277_at 1.9 1.5 1.4 1.9 ω-oxidation [89, 90]
G6pt1 (Slc37a4) 1417042_at -1.5 nc nc nc Glycogenolysis [91]
Nadc1 (Slc13a2) 1418857_at -2.1 -2.2 nc nc Dicarboxylates uptake for Krebs cycle [92]
Cholesterol flux
Npc1l1 1438514_at -1.5 -1.4 -1.6 nc Apical cholesterol uptake [93]
Abca1 1450392_at 12.1 3.2 nc nc Basolateral cholesterol efflux [56, 58]
Glucose transport
Sglt1 (Slc5a1) 1455431_at -1.4 nc nc nc Apical glucose uptake [94]
Glut2 (Slc2a2) 1449067_at -1.4 nc nc nc Basolateral glucose efflux [95]
Glut1 (Slc2a1) 1426599_a_at -1.5 nc nc nc Glucose transport [95]
Sglt4 (Slc5a9) 1439494_at -1.7 -1.7 -2.0 nc Glucose + mannose transport [96]
Amino acid metabolism
Eaac1 (Slc1a1) 1448299_at -1.4 nc nc nc Apical glutamate uptake [97]
Pat1 (Slc36a1) 1428793_at nc -1.6 -1.8 nc Apical neutral amino acids uptake [98]
Lat2 (Slc7a8) 1417929_at -1.6 -1.6 -2.0 nc Basolateral neutral amino acids efflux [99]
Tat1 (Slc16a10) 1436368_at -1.7 -1.4 -1.8 nc Basolateral aromatic amino acids efflux [100]
y+Lat1 (Slc7a7) 1447181_s_at 1.5 nc nc nc Basolateral cationic amino acids efflux [99]
Aralar1 (Slc25a12) 1428440_at -1.3 nc nc nc Malate-aspartate shuttle: provides cytosolic aspartate [62]
Intestinal motility
Sert (Slc6a4) 1417150_at -1.4 -1.2 -1.3 nc Serotonine uptake [66]
Dat1 (Slc6a3) 1417415_at nc 1.8 nc 2.6 Dopamine uptake [68]
Nas1 (Slc13a1) 1430804_at -2.1 -2.0 nc -2.3 Apical sulphate uptake [101]
Oxidative stress
Dic (Slc25a10) 1416954_at 1.6 1.5 nc nc Pyruvate metabolism [62]
Kmcp1 (Slc25a30) 1420836_at 5.5 nc nc nc ?
Mct13 (Slc16a13) 1453056_at 10.7 1.5 1.8 nc ?
Svct1 (Slc23a1) 1421912_at nc 1.7 nc nc Apical vitamin C uptake [102]
Svct2 (Slc23a2) 1445589_at 1.4 nc nc nc Basolateral vitamin C uptake [102]
Cyp2c29 1417651_at nc 3.2 nc nc Phase I metabolism
Cyp2c65 1429994_s_at 2.6 2.3 2.5 1.7 Phase I metabolism
Cyp2d22 1419039_at 1.7 1.5 nc nc Phase I metabolism
Akr1b8 1448894_at 13.4 3.2 5.1 nc ?
Akr1c12 1422000_at -1.5 nc nc nc Aldo-ketoreductase activity (Phase II)
Akr1c13 1418672_at -1.7 nc nc nc Aldo-ketoreductase activity (Phase II)
Ephx1 1422438_at 1.7 1.6 1.9 nc Epoxide hydrolase activity (Phase II)
Ephx2 1448499_a_at 1.5 1.4 nc nc Epoxide hydrolase activity (Phase II)
Gsta1///Gsta2 1421041_s_at nc 1.2 1.3 nc Glutathione transferase activity (phase II)
Gsta3 1423436_at nc nc 1.8 nc Glutathione transferase activity (phase II)
Gsta4 1416368_at nc nc 1.5 nc Glutathione transferase activity (phase II)
Gstk1 1452823_at 1.3 1.3 1.5 nc Glutathione transferase activity (phase II)
Gstm1 1448330_at nc 1.7 nc nc Glutathione transferase activity (phase II)
Gstm3 1427473_at nc 2.4 2.6 nc Glutathione transferase activity (phase II)
Gstm4 1424835_at 2.0 1.8 1.8 nc Glutathione transferase activity (phase II)
Gstm5 1416842_at -1.3 nc nc nc Glutathione transferase activity (phase II)
Gstm6 1422072_a_at nc 1.3 nc nc Glutathione transferase activity (phase II)
Gstt2 1417883_at 1.2 nc nc nc Glutathione transferase activity (phase II)
Mgst1 1415897_a_at 1.4 1.3 1.2 nc Glutathione transferase activity (phase II)
Abcg2 1422906_at 1.9 nc 1.3 nc Apical heme secretion [74]
Overview of PPARα-dependently regulated processes related to transport and phase I/II metabolism in the small intestine. All processes are described in 
the results and discussion section. FC = fold change, nc = not changed.
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Dic (Slc25a10), involved in the pyruvate-malate shuttle,
citrate-pyruvate shuttle, and gluconeogenesis from pyru-
vate, is known to protect against oxidative stress [62];
Svct2 (Slc23a2), a basolaterally-located uptake trans-
porter for ascorbic acid [71]; Mct13 (Slc16a13), proposed
to play an important role in communicating information
on the redox state between cells [72]; Abcg2 (Bcrp1), a
secretion transporter of heme and porphyrins located in
the apical membrane [73,74]; and Kmcp1 (Slc25a30),
probably involved in protection from oxidative damage in
situations of increased mitochondrial metabolism [75].
Taken together, we show that many barrier genes involved
in defense against oxidative stress were PPARα-depend-
ently upregulated. These data point towards an important
role of PPARα in the defense against oxidative stress. In
general oxidative stress results in increased cell damage
and apoptosis [69] and our data might explain one of the
mechanisms by which WY14643 suppresses many genes
involved in apoptosis in the small intestine [22].
Longitudinal distribution of the transcriptional regulation 
during PPARα activation is not the same for PPARα-
dependently regulated genes
Finally we investigated the expression along the proximal-
distal axis of PPARα and 4 genes that were PPARα-
dependently regulated by all agonists (Figures 2 and 3).
Expression was measured with qRT-PCR. For this analysis,
the small intestine was divided in 10 equal parts; part 1
represents the proximal side, whereas part 10 represents
the most distal end. Expression of PPARα was maximal in
duodenum and jejunum, and then gradually declined in
ileum, both under basal conditions and after acute activa-
tion with WY14643 (Figure 2). For all treatments only the
expression pattern in treated wild-type and PPARα-null
mice of the 4 genes is reported (Figure 3). Fatp4, Abcd3,
Cyp2c65, and Cyp4f16 are all involved in fatty acid
metabolism; Fatp4 mediates the apical uptake of long
chain fatty acids [76], whereas Abcd3 is involved in the
peroxisomal β-oxidation of long chain fatty acids [77].
The human homolog of Cyp2c65 (CYP2C8) metabolizes
arachidonic acid and generates epoxygenase products
[78]. The rat homolog of Cyp4F16 (Cyp4F5) is involved
in ω-oxidation of prostaglandins [79].
In EPA-, DHA- and WY14643-treated mice we observed a
similar expression pattern of Fatp4 (Figure 3A), which
closely resembled that of PPARα under control and
WY14643-activated conditions. In contrast, OA-treated
wild-type mice did not show this pattern. In all treatments
no significant PPARα-dependent induction of Fatp4 was
observed in the distal part of the small intestine. Abcd3
was uniformly induced by all treatments (Figure 3B). Acti-
vation with WY14643 revealed a robust, equal induction
in all segments in wild-type compared to PPARα-null
mice, whereas these were less for the three natural ago-
nists. Cyp2c65 was predominantly expressed in the prox-
imal part of the small intestine, and showed high
similarity between agonists (Figure 3C). For each agonist
we observed an induction of its expression which was
equal along the complete longitudinal axis. Cyp4F16 was
uniformly expressed along the proximal-distal axis in
treated PPARα-null mice (Figure 3D). However, treatment
of wild-type mice with WY14643 and OA shifted the
expression of Cyp4F16 to more distal regions, whereas
EPA and DHA treatment resulted in significant increased
expression in more proximal segments.
Taken together, the data in Figure 3 show that in general
all agonists provoke a similar effect on expression of 4
PPARα-dependently regulated genes, and this induction
also occurs in more distally-located cells. The latter dem-
onstrates that despite its relatively low expression, PPARα
is still able to regulate gene expression.
Expression of PPARα along the longitudinal axis of control and WY14643-treated wild- ype miceFigure 2
Expression of PPARα along the longitudinal axis of 
control and WY14643-treated wild-type mice. QPCR 
was used to determine the relative expression levels of 
PPARα in sections isolated along the proximal-distal axis of 
the small intestine of wild-type mice that received the con-
trol diet (white, open bars), or were acutely treated (6 hr) 
with WY14643 (black, closed bars) (n = 4 per group). Small 
intestines were divided into 10 equal parts; part 1 refers to 
the most proximal part (duodenum), part 10 refers to the 
most distal (terminal ileum). Messenger RNA levels were 
standardized to cyclophilin; part 1 of the non-treated mice 
was arbitrarily set to 1. Significance of control versus treated 
wild-type mice was determined per segment using an 
unpaired student's t-test. * p-value < 0.05. Data are pre-
sented as mean ± standard error.Page 7 of 13
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In the current study we have identified intestinal barrier
genes that were PPARα-dependently regulated after acute
activation by fatty acids. The functional outcomes inferred
from our data suggest that nutritional-activated PPARα
controls processes ranging from fatty acid oxidation and
cholesterol-, glucose-, and amino acid-transport and
metabolism to intestinal motility and oxidative stress.
Altogether, we showed that PPARα has a great impact in
controlling the barrier function of the gut, and this under-
scores the importance of PPARα for nutrient-mediated
gene regulation in intestine.
Methods
Animals and materials
Pure bred wild-type (129S1/SvImJ) and Pparα-null
(129S4/SvJae) mice [80] were bred and housed as
described [81]. All animal studies were approved by the
Local Committee for Care and Use of Laboratory Animals.
The synthetic triacylglycerols trieicosapentaenoin and tri-
docosahexaenoin were bought from Nu-Chek-Prep, Inc
Expression of PPARα-dependently regulated genes along the longitudinal axis of treated PPARα-null and wild-type miceFigure 3
Expression of PPARα-dependently regulated genes along the longitudinal axis of treated PPARα-null and wild-type mice. QPCR was used 
to determine relative expression levels of PPARα-dependently regulated genes in sections isolated along the proximal-distal axis of the small intestine from 
PPARα-null mice (white, open bars) and wild-type mice (black, closed bars) that were acutely treated (6 hr) with the 4 agonists (n = 4 per group). The small 
intestine was divided into 10 equal parts; part 1 refers to the most proximal part (duodenum), part 10 refers to the most distal (terminal ileum). Messenger 
RNA levels were standardized to cyclophilin; part 1 of the PPARα-null mice was arbitrarily set to 1. White bars represent the PPARα-null mice, black bars 
represent the wild-type mice. Significance of treated WT versus treated KO mice was determined per segment using an unpaired student's t-test. * p-value 
< 0.05. Data are presented as mean ± standard error. A) fatty acid transport protein 4 (Fatp4). B) ATP-binding cassette, sub-family D, member 3 (Abcd3; 
ALD). C) cytochrome P450, family 2, subfamily c, polypeptide 65 (Cyp2c65). D) cytochrome P450, family 4, subfamily f, polypeptide 16 (Cyp4f16).Page 8 of 13
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drecht, the Netherlands). These are synthetic triacylglycer-
ols with three identical acyl moieties, namely
eicosapentaenoic acid (EPA), docosahexanoic acid (DHA)
and oleic acid (OA), which are released as free fatty acids
upon digestion in the small intestinal lumen. All three
fatty acids have been reported to bind PPARα with varying
affinities in the micromolar range [30-33]. WY14643 was
obtained from Chemsyn (Lenexa, KS).
Experimental design and tissue handling
Four months-old male wild-type and PPARα-null mice
were used in this study (n = 4–5 per group). Two weeks
before the start of the experiment all mice were put on a
background diet, which was a modified AIN76A diet
(Research diet services, Wijk bij Duurstede, The Nether-
lands). The AIN76A diet contains 5% w/w corn oil (~10
energy%) [82], which is a relatively low amount of fat. In
the current study we replaced the corn oil by the same
amount of olive oil (predominantly consisting of oleic
acid), since Ren et al [83] demonstrated that an olive oil-
rich diet did not regulate established PPARα target genes.
The modified AIN76A diet was thus assumed to be a 'poor
PPARα-activating' diet, and therefore we hypothesized the
number of genes PPARα-dependently regulated by OA
would be nominal. However, since the amount of OA in
the diet was lower than the amount dosed by gavage (see
below), some genes were expected to be regulated.
At the day of the experiment mice were fasted for four
hours. At 9 AM mice were dosed by oral gavage with 400
μl of the synthetic triacylglycerols triolein, trieicosapen-
taenoin, or tridocosahexaenoin, or 400 μl of a 0.1%
WY14643 suspension in 0.5% carboxymethyl cellulose
(Sigma-Aldrich, Zwijndrecht, the Netherlands). The vol-
ume of all doses (400 μl) equalled the maximum recom-
mended volume for gastric gavages for mice [84]. For the
fatty acids these doses corresponded to approximately
12.5 g/kg body weight. To put this amount into perspec-
tive, data on food intake (not shown) revealed that the
mice consumed approximately 4 gram of the modified
AIN76A diet per day, which corresponds to approximately
200 mg (6.7 g/kg body weight) of fat. The amount of
WY14643 the mice received (approximately 130 mg/kg
body weight) was based on previously published short-
term study [85].
Six hours after the gavage the mice were anaesthetized
with a mixture of isofluorane (1.5%), nitrous oxide (70%)
and oxygen (30%). Small intestines were isolated and
flushed with ice-cold phosphate-buffer saline and subse-
quent tissue handlings were performed on ice. Remaining
fat and pancreatic tissue was carefully removed from the
intestines. For RNA analyses of total tissue, we used full-
length small intestine (microarray analyses), or sections
obtained after dividing the small intestine into 10 equal
parts (studying gene expression distribution along the
proximal-distal axis). All small intestinal samples were
snap-frozen in liquid nitrogen and stored at -80°C until
RNA isolation.
RNA isolation, Affymetrix GeneChip oligoarray 
hybridization and scanning, and quantitative real-time 
PCR
RNA isolation, Affymetrix GeneChip oligoarray hybridi-
zation and scanning, and quantitative real-time PCR were
performed as described previously [81]. The sequences of
primers used in qRT-PCR are available on request. For
microarray analyses, RNA was isolated from the full-
length small intestine. RNA was hybridized on an Affyme-
trix GeneChip Mouse Genome 430 2.0 array. This array
detects 45,038 transcripts that represent 16,579 known
genes. For each experimental group, four or five biological
replicates were hybridized for wild-type and PPARα-null
mice, and in total 35 arrays were used. Array data have
been submitted to the Gene Expression Omnibus, acces-
sion number GSE9533.
Analyses of microarray data
Microarrays were analyzed as described previously [81].
To compile a list of transport and phase I/II metabolism
(barrier) genes represented on the array, annotation infor-
mation from Affymetrix (release of July 2006) was que-
ried for SLC transporters, ABC transporters, CypP450s, the
phase II metabolism enzymes glutathione S-transferases,
sulfotransferases, epoxide hydrolases, aldo-keto reduct-
ases, N-acetyltransferases, and glucuronosyl transferases.
Also glutathione reductase, glutathione synthetase, and
glutathione peroxidases were included in this set. The
final set consisted of 944 probesets, encoding for 529
unique genes. To study significantly expressed genes, only
probesets with an expression estimate higher than 32 in
either of the 8 experimental groups were selected for fur-
ther analysis. This cut-off value was based qPCR experi-
ments, because regulation of genes with an expression
estimate >32 on the array could all be confirmed by qPCR
[81]. The filtering was done after normalization and data
analysis. Probesets that had a Bayesian comparison p-
value <0.01 were considered to be significantly regulated;
no cut-off value of the fold change was used. Of these,
probesets that were changed in treated wild-type mice
compared to treated PPARα-null mice, were designated
PPARα-dependently regulated. QPCR data confirming
our array analysis is presented in Table 2 and additional
data, Table 7. Differences on the number of regulated
genes between gene sets were tested for significance by a
one-tailed binominal test. Interpretations of functional
outcomes focused on groups of genes that are known to
be functionally related (i.e. having a similar function or
participating in the same pathway).Page 9 of 13
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